## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**

## **Entrectinib for treating NTRK fusion-positive solid tumours ID1512**

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company	General
• Roche (entrectinib)	Allied Health Professionals Federation
Patient/carer groups	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
<ul><li>Patient/carer groups</li><li>Anthony Pilcher Bone Cancer Trust</li></ul>	Association of Renal Industries
Black Health Agency	<ul> <li>Board of Community Health Councils in</li> </ul>
Bob Champion Cancer Trust	Wales
Breast Cancer Care	British National Formulary
Breast Cancer Now	Care Quality Commission
Breast Cancer UK	Department of Health, Social Services
British Lung Foundation	and Public Safety for Northern Ireland
British Skin Foundation  British Skin Foundation	Health and Safety Executive
<ul><li>Butterfly Thyroid Cancer Trust</li><li>Cancer 52</li></ul>	<ul> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products</li> </ul>
Cancer 52     Cancer Black Care	<ul> <li>Medicines and Healthcare products Regulatory Agency</li> </ul>
Cancer Black Care     Cancer Equality	<ul> <li>National Association of Primary Care</li> </ul>
Cancer Laryngectomee Trust	National Pharmacy Association
Changing Faces	NHS Alliance
CLIC Sargent	NHS Confederation
Genetic Alliance UK	Scottish Medicines Consortium
Get-A-Head	Welsh Health Specialised Services
Haven	Committee
• HAWC	Welsh Kidney Patients Association
Helen Rollason Cancer Charity	Possible comparator companies
Independent Cancer Patients Voice	None
Kidney Cancer Support Network     Kidney Cancer LIK	- None
Kidney Care UK     Kidney Care UK	Relevant research groups
<ul><li>Kidney Care UK</li><li>Let's Face It</li></ul>	Against Breast Cancer
Macmillan Cancer Support	Bone Cancer Research Trust
Maggie's Centres	Bone Research Society
Marie Curie	Breast Cancer Hope
Mouth Cancer Foundation	Breast Cancer Research Trust     Canada Research Canada Cana
Muslim Council of Britain	Cochrane Breast Cancer Group     Cochrane Lyng Cancer Group
National Association Of	Cochrane Lung Cancer Group     Cochrane Prostatic Diseases Uralogic
Laryngectomee Clubs	<ul> <li>Cochrane Prostatic Diseases Urologic Cancers Group</li> </ul>
National Kidney Federation	Canocia Cioup

Provisional matrix for the technology appraisal of entrectinib for treating NTRK fusion-positive solid tumours ID1512. Issue date: November 2018

#### Consultees Commentators (no right to submit or appeal) Orchid – Fighting Male Cancer Cochrane Skin Group **Prostate Cancer UK Genomics England** Head and Neck Cancer Research Prostate Help Association Foundation Roy Castle Lung Cancer Foundation Institute of Cancer Research Sarcoma UK South Asian Health Foundation Melanoma Fund MRC Clinical Trials Unit Specialised Healthcare Alliance Swallows Head and Neck Cancer National Cancer Research Institute Support Group National Cancer Research Network **Tenovus Cancer Care** National Institute for Health Research Ovarian & Prostate Cancer Research The Royal Marsden Cancer Charity Together for Short Lives Trust **UK Lung Cancer Coalition** Pro Cancer Research Fund Women's Health Concern Prostate Cancer Research Centre Research Institute for the Care of Older Professional groups People Association of Anaesthetists Skin Cancer Research Fund **Association of Cancer Physicians** Skin Treatment & Research Trust Association of Respiratory Nurse <u>Associated Public Health Groups</u> Specialists • Association of Surgeons of Great Public Health England Public Health Wales Britain and Ireland British Association of Dermatologists British Association of Endocrine and **Thyroid Surgeons** British Association of Skin Cancer Specialist Nurses **British Association of Surgical** Oncology British Association of Urological Surgeons British Dermatological Nursing Group **British Geriatrics Society** British Institute of Musculoskeletal Medicine British Institute of Radiology **British Orthopaedic Association** British Orthopaedic Oncology Society **British Prostrate Group** British Psychosocial Oncology Society **British Renal Society** British Sarcoma Group British Society for Dermatological Surgery British Society of Skeletal Radiologists British Society of Urogenital Radiology

<ul> <li>British Thoracic Oncology Group</li> <li>British Thoracic Society</li> <li>British Thyroid Association</li> <li>British Uro-oncology Group</li> <li>Cancer Research UK</li> <li>Melanoma Focus</li> <li>National Lung Cancer Forum for Nurses</li> <li>Pelican Cancer Foundation</li> <li>Primary Care Dermatology Society</li> <li>Renal Association</li> <li>Royal College of Anaesthetists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Pathologists</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Health Forum</li> <li>UK Oncology Nursing Society</li> <li>UK Renal Pharmacy Group</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	Consultees	Commentators (no right to submit or appeal)
<ul> <li>NHS Lingland</li> <li>NHS Hillingdon CCG</li> <li>NHS Rushcliffe CCG</li> <li>Welsh Government</li> </ul>	<ul> <li>British Thoracic Society</li> <li>British Thyroid Association</li> <li>British Uro-oncology Group</li> <li>Cancer Research UK</li> <li>Melanoma Focus</li> <li>National Lung Cancer Forum for Nurses</li> <li>Pelican Cancer Foundation</li> <li>Primary Care Dermatology Society</li> <li>Renal Association</li> <li>Royal College of Anaesthetists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Health Forum</li> <li>UK Oncology Nursing Society</li> <li>UK Renal Pharmacy Group</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> <li>NHS Hillingdon CCG</li> <li>NHS Rushcliffe CCG</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

## PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

## **Consultees**

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and social care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

<sup>&</sup>lt;sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.